List of Excipients in Branded Drug LODOSYN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Bausch Health US LLC	LODOSYN	carbidopa	25010-711	FD&C YELLOW NO. 6
Bausch Health US LLC	LODOSYN	carbidopa	25010-711	MAGNESIUM STEARATE
Bausch Health US LLC	LODOSYN	carbidopa	25010-711	POWDERED CELLULOSE
Bausch Health US LLC	LODOSYN	carbidopa	25010-711	STARCH, CORN

Lodosyn Excipient Strategy and Commercial Opportunities

Last updated: September 5, 2026

Lodosyn is an oral carbidopa product used with levodopa in Parkinson's disease. Its core small-molecule composition has no meaningful remaining regulatory exclusivity, and commercial opportunity is concentrated in differentiated dosage forms, stability improvements, combination products, supply reliability, and patient-convenience features. The strongest excipient strategy is a robust immediate-release tablet platform that protects carbidopa from oxidation, supports low-dose content uniformity, and enables flexible coadministration with levodopa.

What is Lodosyn and how is carbidopa used?

Lodosyn contains carbidopa, a peripheral aromatic L-amino acid decarboxylase inhibitor. Carbidopa is administered with levodopa to reduce peripheral conversion of levodopa to dopamine and increase the fraction of levodopa reaching the brain. Lodosyn is not generally positioned as a stand-alone Parkinson's treatment; its commercial role is as an adjunct to levodopa therapy.[1]

Attribute	Lodosyn
Active ingredient	Carbidopa
Dosage form	Immediate-release tablet
Established strength	25 mg
Therapeutic area	Parkinson's disease and parkinsonian syndromes
Primary use	Adjunct to levodopa
Regulatory pathway	FDA-approved small-molecule drug
Biologic status	Not applicable
Biosimilar exposure	None
Main competitive products	Generic carbidopa; carbidopa/levodopa combinations
Primary commercial issue	Low differentiation in a mature market

Carbidopa is commonly administered in fixed-dose products with levodopa, including carbidopa/levodopa tablets and orally disintegrating formulations. Lodosyn has strategic value where clinicians need to adjust carbidopa independently of levodopa.

What is the FDA regulatory and Orange Book status of Lodosyn?

Lodosyn was approved under NDA 017808. Its FDA exclusivity period expired decades ago. The product is therefore exposed to generic competition and does not have a current new chemical entity exclusivity position.

The Orange Book framework is relevant because any listed patents or exclusivity associated with Lodosyn could affect abbreviated new drug application timing. For a product with an approval history dating to the 1970s, the principal regulatory barriers are generally bioequivalence, manufacturing consistency, supply reliability, and market access rather than remaining pioneer exclusivity.[2]

Lodosyn regulatory position

Regulatory issue	Commercial implication
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	No established orphan exclusivity identified
Pediatric exclusivity	No current commercial relevance identified
Biosimilar pathway	Not applicable
Paragraph IV exposure	Relevant only to any active Orange Book-listed patent claims
Generic pathway	ANDA pathway is the principal route
Regulatory differentiation	Requires a new dosage form, formulation, strength, or other qualifying change

A generic Lodosyn-equivalent tablet would ordinarily compete on approval status, price, product availability, wholesaler coverage, and pharmacy substitution. A reformulated product may need a 505(b)(2) strategy if it relies on a change in dosage form, route, dosing schedule, or formulation that is not fully covered by an ANDA reference-product approach.[3]

What excipients are strategically important in Lodosyn tablets?

The exact inactive-ingredient profile should be taken from the current FDA labeling and the applicable manufacturer's approved product record. Public product information identifies Lodosyn as an immediate-release oral tablet, but excipient composition can vary by manufacturer, post-approval manufacturing change, and market presentation.[1]

For a carbidopa tablet, the most important excipient functions are:

1. Protection against oxidative degradation.
2. Uniform distribution of a relatively low active dose.
3. Rapid and reproducible disintegration.
4. Adequate mechanical strength at low tablet mass.
5. Compatibility with common Parkinson's disease administration patterns.
6. Low risk of excipient-related tolerability problems in older patients.

Functional excipient platform

Formulation function	Candidate excipient classes	Strategic purpose
Dilution and compressibility	Microcrystalline cellulose, mannitol, lactose where compatible	Supports content uniformity and tablet manufacture
Dry binding	Povidone, copovidone, pregelatinized starch	Improves granule or tablet strength
Disintegration	Crospovidone, croscarmellose sodium, sodium starch glycolate	Enables immediate release
Lubrication	Magnesium stearate, sodium stearyl fumarate	Controls ejection and sticking
Glidancy	Colloidal silicon dioxide	Improves powder flow
Moisture management	Low-moisture excipient grades, protective packaging	Reduces hydrolytic and physical stability risk
Oxidative-risk management	Chelation and oxygen-control strategy, where justified	May reduce degradation pathways
Film protection	Hypromellose-based coating systems	Improves handling, identification, and light or moisture protection
Taste management	Mannitol, polymer coating, ion-exchange or lipid systems	Relevant to orally disintegrating or chewable products

The preferred first-generation platform is an immediate-release, low-moisture tablet based on microcrystalline cellulose or mannitol, a high-efficiency disintegrant, a low-use-level binder, colloidal silicon dioxide, and a controlled lubricant system. The formulation should avoid unnecessary excipient complexity because the reference product has a mature safety record and the target patient population is older and frequently receives multiple medicines.

How should excipients address carbidopa stability?

Carbidopa formulation development should treat oxidation as a central risk. The molecule contains functional groups that can be vulnerable to oxidative degradation, and formulation variables such as oxygen exposure, trace metals, moisture, light, pH, and processing temperature can affect stability.

A commercial formulation program should evaluate:

• Oxygen exposure during wet granulation, drying, blending, compression, and packaging.
• Trace-metal contribution from excipients and manufacturing equipment.
• Peroxide levels in povidone, crospovidone, polyethylene glycol, and other polymeric excipients.
• Moisture uptake of the tablet core and coating.
• Light transmission through the primary container and secondary packaging.
• Compatibility of colorants, coatings, and antioxidants.
• Stability after bottle opening and repeated patient handling.

Packaging and excipient choices

A bottle presentation with a desiccant may be suitable for a conventional tablet, but blister packaging can offer better unit-dose protection and adherence support. An aluminum-aluminum blister may provide stronger moisture and oxygen barriers than standard high-density polyethylene packaging, although the cost and patient-use profile must be evaluated.

A stability-led excipient strategy should use supplier controls for:

• Peroxide content.
• Water activity.
• Heavy metals.
• Particle-size distribution.
• Microbial quality.
• Lot-to-lot functional performance.

The formulation should not rely on an antioxidant or chelator without demonstrating that the additive improves the finished product and does not create a new impurity or regulatory burden. A robust barrier package may offer a more defensible and scalable solution than a high-excipient formulation.

What formulation patents could protect a Lodosyn follow-on product?

A conventional 25 mg carbidopa tablet is unlikely to support broad composition-of-matter protection. Patent value would instead come from narrow, technically reproducible claims tied to a measurable product or manufacturing attribute.

Potential protection areas include:

Oxidation-resistant carbidopa formulation

Claims could target:

• Specified impurity limits after accelerated storage.
• Defined oxygen transmission or moisture ingress parameters.
• A particular combination of excipient grades.
• A low-peroxide polymeric excipient system.
• A defined chelator or antioxidant concentration.
• A tablet core with specified water activity.

These claims are more defensible when linked to unexpected stability performance rather than a routine substitution of one filler or disintegrant for another.

Orally disintegrating tablet

An orally disintegrating carbidopa tablet could target patients with dysphagia, delayed gastric emptying, or difficulty swallowing conventional tablets. Candidate excipient systems include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking polymers.

The main technical risks are:

• Carbidopa bitterness.
• Adequate mechanical strength.
• Moisture sensitivity.
• Fast disintegration without excessive friability.
• Dose uniformity at low tablet weight.
• Acceptable mouthfeel for chronic use.

Modified-release or pulsatile delivery

Modified-release carbidopa alone has a weaker commercial rationale than a formulation that changes levodopa exposure. Carbidopa is commonly used to support levodopa therapy, so a modified-release carbidopa product would need a clear pharmacokinetic or clinical benefit. A release profile that is not synchronized with the accompanying levodopa product may add complexity without improving outcomes.

Sprinkle or dispersible formulation

A capsule containing coated pellets, granules, or mini-tablets could support administration to patients unable to swallow tablets. The formulation would require data on dose uniformity, stability after opening, food effects, and compatibility with common soft foods or liquids.

Combination product

A carbidopa/levodopa product could use excipient engineering to provide:

• Separate release profiles for the two active ingredients.
• Multiple strengths in a single platform.
• Improved tablet identification.
• Reduced pill burden.
• Better stability for both active ingredients.
• An orally disintegrating or sprinkle presentation.

Combination-product claims may have greater commercial value than a stand-alone Lodosyn reformulation, but they also face more demanding bioequivalence and clinical-development requirements.

What commercial opportunities exist for Lodosyn-related products?

The commercial opportunity is segmented rather than broad. A standard generic 25 mg tablet is likely to compete in a price-sensitive market. Higher-value opportunities depend on solving a specific administration, supply, or adherence problem.

Opportunity	Value proposition	Development burden	Commercial attractiveness
Standard generic 25 mg tablet	Low-cost substitution	Low to moderate	Moderate volume, low margin
Premium oxidation-controlled tablet	Longer shelf life and supply reliability	Moderate	Moderate
Orally disintegrating tablet	Easier administration	Moderate to high	High if clinically accepted
Sprinkle or dispersible product	Supports dysphagia population	Moderate to high	Niche but differentiated
Carbidopa/levodopa combination	Reduces pill burden	High	High strategic value
Multiple carbidopa strengths	Dose titration flexibility	Low to moderate	Moderate
Hospital and long-term-care supply	Reliable availability	Low to moderate	Stable institutional demand
Authorized generic	Trusted supply and contracting flexibility	Low to moderate	Moderate
Regional licensing or contract manufacturing	Market access and capacity	Low to moderate	Depends on territory

Revenue exposure

Publicly available sources do not establish current Lodosyn net sales, manufacturer revenue, or product-level profitability. The commercial model should therefore use scenario analysis based on prescription volume, generic price erosion, wholesaler discounts, and channel mix rather than relying on a reported Lodosyn revenue figure.

A conventional generic strategy may produce limited gross margin because the active ingredient and tablet technology are established. A differentiated formulation can support higher pricing if it obtains regulatory protection, secures favorable formulary treatment, or reaches a patient group poorly served by standard tablets.

When does Lodosyn lose exclusivity, and what generic entry risks exist?

Lodosyn's original exclusivity has expired. The relevant entry risks are therefore:

• ANDA approval for a conventional carbidopa tablet.
• New generic strengths.
• Authorized generic competition.
• Substitution by carbidopa/levodopa products.
• Contract-manufacturing price competition.
• Shortages or discontinuation of an incumbent supplier.
• State substitution rules and pharmacy purchasing behavior.

A Paragraph IV challenge would matter only if an active, Orange Book-listed patent blocked approval or imposed a 30-month stay after timely notice and litigation. For an old immediate-release product, the larger practical risk is usually commercial erosion from approved generics rather than patent litigation.[2,4]

Which companies are challenging or competing with Lodosyn?

The relevant competitive set includes manufacturers of:

• Generic carbidopa tablets.
• Generic carbidopa/levodopa tablets.
• Orally disintegrating carbidopa/levodopa products.
• Other levodopa combinations, including products with additional peripheral decarboxylase or catechol-O-methyltransferase inhibition.

The competitive threat is not limited to products labeled as Lodosyn equivalents. Physicians may use a carbidopa/levodopa product to provide the same peripheral decarboxylase inhibition while simplifying dosing. A stand-alone carbidopa product retains value when the prescriber needs independent adjustment of carbidopa exposure or when the levodopa regimen is separately managed.

Company participation and current product availability can change by strength, national drug code, manufacturing site, and supply status. FDA's Drugs@FDA, Orange Book, National Drug Code Directory, and current labeling should control any live competitor or approval analysis.[1,2,5]

How does Lodosyn compare with carbidopa/levodopa products?

Criterion	Lodosyn	Carbidopa/levodopa combination
Dosing flexibility	High for independent carbidopa adjustment	Lower because actives are fixed together
Pill burden	May increase total tablets	Usually lower
Generic competition	Mature	Very mature
Formulation differentiation	Possible through ODT, sprinkle, or stability	Possible through release control and dose ratios
Clinical positioning	Adjunctive carbidopa	Core levodopa replacement therapy
Commercial scale	Narrower	Broader
Patent opportunity	Formulation and administration claims	Formulation, release profile, ratio, and method-of-use claims

The strongest commercial rationale for a new Lodosyn-related product is a specific need that a fixed-dose carbidopa/levodopa product cannot address. Independent dosing is the principal clinical distinction.

What manufacturing and intellectual-property barriers matter?

Manufacturing barriers are manageable but not trivial. Carbidopa's low dose relative to tablet mass makes content uniformity important. The manufacturer must control segregation, blend uniformity, lubrication time, and tablet-weight variation. Oxidative impurities can also create batch-release and shelf-life problems.

Key manufacturing controls include:

• Validated blend uniformity.
• Low-shear or controlled-shear processing.
• Excipient peroxide limits.
• Controlled granulation endpoint.
• Short exposure to elevated temperature.
• Low oxygen and moisture during critical operations.
• Stability-indicating analytical methods.
• Container-closure integrity.
• Defined impurity and degradation-product limits.

The IP estate for a conventional Lodosyn-equivalent tablet is likely weak unless supported by a newer formulation or manufacturing invention. A stronger estate would combine:

1. Composition claims.
2. Product-by-process or manufacturing claims.
3. Defined dissolution or disintegration specifications.
4. Stability and impurity performance claims.
5. Method-of-use claims tied to a differentiated presentation.

Method-of-use patents must address statutory and obviousness risks. A claim based only on using carbidopa with levodopa is likely vulnerable because that use is established. A claim tied to a novel dosing schedule, patient subgroup, or clinically demonstrated pharmacokinetic advantage would require stronger evidence.

What licensing opportunities exist for Lodosyn?

Licensing opportunities are most credible in four structures:

• Regional rights for a differentiated carbidopa formulation.
• Co-development of an orally disintegrating or sprinkle product.
• Supply and distribution agreements for a generic tablet.
• Combination-product partnerships involving carbidopa/levodopa.

A license should be valued against the actual source of differentiation. A conventional generic license should focus on manufacturing cost, regulatory status, supply continuity, and territory. A reformulation license should focus on patent scope, freedom to operate, stability data, bioequivalence risk, and reimbursement positioning.

No specific active licensing transaction should be attributed to Lodosyn without a current public agreement or company disclosure.

What is the recommended Lodosyn excipient and product strategy?

The preferred sequence is:

First platform: robust immediate-release tablet

Develop a 25 mg tablet with:

• Low-moisture excipients.
• A high-performance disintegrant.
• Controlled lubricant concentration.
• Excipient-grade peroxide limits.
• Protective film coating if needed.
• Blister or high-barrier bottle packaging.
• A stability program focused on oxidative impurities.

This platform has the lowest development risk and supports an ANDA or equivalent generic strategy.

Second platform: orally disintegrating tablet

Use mannitol-based mouthfeel, rapid disintegration, and taste-masking technology. This product should target patients with swallowing difficulty and should be evaluated for adherence and administration preference, not only laboratory disintegration time.

Third platform: combination product

Evaluate carbidopa/levodopa only after establishing a clinically meaningful release or dosing advantage. The opportunity is larger, but the development program, bioequivalence work, and competitive environment are more demanding.

IP strategy

Avoid relying on routine excipient substitution. Seek claims based on demonstrated stability, defined impurity control, rapid disintegration, taste masking, or a clinically relevant delivery profile. The commercial plan should assume that broad Lodosyn composition claims are unavailable.

Key Takeaways

• Lodosyn is a 25 mg immediate-release carbidopa tablet used with levodopa.
• Its original regulatory exclusivity has expired, and biosimilar risk does not apply.
• Conventional generic competition is the main threat.
• Excipient development should prioritize oxidative stability, low-dose uniformity, rapid disintegration, and moisture control.
• The most credible differentiated products are orally disintegrating, sprinkle, dispersible, or combination carbidopa/levodopa formulations.
• Patent value is likely to come from formulation, manufacturing, stability, and delivery claims rather than the carbidopa molecule.
• Current product availability, Orange Book listings, active patents, and competitor participation require confirmation against live FDA and manufacturer records.
• Public sources do not establish current Lodosyn net sales or product-level revenue exposure.

FAQs

Is Lodosyn still protected by a composition-of-matter patent?

No current composition-of-matter exclusivity is commercially relevant for Lodosyn. Carbidopa is an established active ingredient, and the product's original exclusivity period expired long ago.

Can a company launch a generic 25 mg carbidopa tablet?

Yes, subject to FDA approval, bioequivalence, manufacturing compliance, labeling requirements, and any active patent or regulatory listing applicable to the reference product.

Is carbidopa a biologic requiring a biosimilar application?

No. Carbidopa is a synthetic small molecule. A follow-on product would generally use an ANDA or, for a materially changed formulation, a 505(b)(2) application.

Would an orally disintegrating Lodosyn product receive new exclusivity?

A new dosage form does not automatically receive exclusivity. Any exclusivity would depend on the applicable FDA approval basis and qualifying innovation. Patent protection would require novel, non-obvious, and adequately supported claims.

What is the most commercially attractive excipient innovation for carbidopa?

An orally disintegrating, taste-masked carbidopa tablet with strong moisture and oxidative stability has the clearest differentiation potential. A conventional stability-enhanced tablet is easier to develop but is more exposed to generic price competition.

References

1. U.S. Food and Drug Administration. (n.d.). Lodosyn (carbidopa) prescribing information. Drugs@FDA and product labeling database.

2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations. Orange Book.

3. U.S. Food and Drug Administration. (2023). Applications covered by section 505(b)(2). FDA guidance and regulatory materials.

4. U.S. Food and Drug Administration. (n.d.). Abbreviated new drug application submissions and Paragraph IV certifications. FDA regulatory guidance.

5. U.S. Food and Drug Administration. (n.d.). National Drug Code Directory. FDA drug listing database.